Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
PYPD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
globenewswire.com
8 hours ago
globenewswire.com
13 hours ago
seekingalpha.com
14 hours ago
Quote Panel
Key Metrics
Relative Strength
PYPD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
NaN%2025-Revenue
-112%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
10.00(231.13%)
Number of analyst
1
Last analyst upgrade/downgrade
Craig-Hallum
initialisePrevious: Not converted
2024-11-04
Now: Buy
Raymond James
downgradePrevious: Not converted
2022-09-06
Now: Outperform
Guggenheim
upgradePrevious: Not converted
2022-09-02
Now: Neutral
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-9.61
vsĀ -21.32
Q1.23
N/A
-8.41
vsĀ -18.92
Q2.23
N/A
-3.90
vsĀ -18.32
Q3.23
N/A
-3.40
vsĀ -14.41
Q4.23
N/A
-3.97
vsĀ -9.61
Q1.24
N/A
-1.37
vsĀ -8.41
Q2.24
N/A
-1.25
vsĀ -3.90
Q3.24
+100%
NA
vsĀ -3.40
Q4.24
N/A
-1.08
vsĀ -3.97
Q1.25
N/A
-0.90
vsĀ -1.37
Sales Growth
YoY
Current
Estimates
Q2.22
NA
NAĀ vsĀ NA
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
NAĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q4.22
-111%
-1.11
vsĀ -0.81
Q1.23
-53%
-0.53
vsĀ -1.11
Q2.23
-70%
-0.70
vsĀ -0.53
Q3.23
-158%
-1.58
vsĀ -0.70
Q4.23
+303%
3.03
vsĀ -1.58
Q1.24
-90%
-0.90
vsĀ 3.03
Q2.24
-393%
-3.93
vsĀ -0.90
Q3.24
-360%
-3.60
vsĀ -3.93
Institutionnal Ownership
QoQ
Q3.21
19
19
vsĀ 22
-14%
Q4.21
30
30
vsĀ 19
58%
Q1.22
31
31
vsĀ 30
3%
Q2.22
30
30
vsĀ 31
-3%
Q3.22
21
21
vsĀ 30
-30%
Q4.22
14
14
vsĀ 21
-33%
Q1.23
10
10
vsĀ 14
-29%
Q2.23
13
13
vsĀ 10
30%
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.09Ā ( 3.07%)
Relative Strenght
14
Volume Buzz
28%
Earning Acce
Yes
Dist 52w H.
67%